Table 4.

Logistic regression analysis for predicting the likelihood of patients experiencing intolerable side effect of topical ciclosporin/Ikervis (total n=463 patients)

Parameters	OR (95% CI)	P value
Age, years		0.006
0–18	3.57 (1.03 to 12.43)	0.045
>18 to 30	7.50 (2.52 to 22.31)	<0.001
>31 to 50	3.30 (1.23 to 8.87)	0.018
>51 to 70	4.12 (1.69 to 10.04)	0.002
>70	Reference	–
Gender
Female	0.99 (0.57 to 1.71)	0.97
Male	Reference	–
Indications		0.001
Dry eye disease	Reference	–
AED	3.81 (1.79 to 8.11)	0.001
OMMP/SJS	3.81 (1.65 to 8.82)	0.002
Post-keratoplasty*	–	–
Others	1.34 (0.51 to 3.50)	0.55
Treatment frequency
Once a day	Reference	–
Twice a day	1.08 (0.63 to 1.85)	0.79
>Twice a day*	–	–

*No patient experienced intolerable side effect in this group and therefore analysis was not possible.

AED, allergic eye disease (which included vernal keratoconjunctivitis and atopic keratoconjunctivitis; OMMP, ocular mucous membrane pemphigoid; SJS, Steven-Johnson syndrome.